SUNNYVALE, Calif.–(BUSINESS WIRE)– The Parkinson’s Institute and Clinical Center and Denali Therapeutics
today announced a partnership to explore new clinical endpoints for
studies in patients with Parkinson’s Disease (PD).
The Institute and Denali aim to support the development of new PD
therapeutics by better understanding the potential of new endpoints for
clinical studies. Known clinical endpoints for PD can be affected by
current standard treatments which, in turn, may confound the measurement
of new therapeutics’ impact.
The agreement brings together the unique expertise of the Institute and
its broad patient experience with Denali as it continues the development
of its LRRK2 inhibitor clinical program for Parkinson’s Disease.
“This collaboration will allow us to explore new clinical endpoints that
may help determine whether therapeutics like Denali’s LRRK2 inhibitors
have a measurable effect on Parkinson’s patients,” said Chief Executive
Officer, Parkinson’s Institute and Clinical Center, Carrolee Barlow,
“We are very enthusiastic about partnering with the Parkinson’s
Institute, which has done so much to support and foster the development
of new approaches to drug development. Having demonstrated our lead
LRRK2 inhibitor in the clinic can reduce LRRK2 kinase activity, we are
looking forward to exploring the potential of new endpoints for clinical
studies in patients,” said Denali Chief Medical Officer and Head of
Development, Carole Ho, M.D.
Today’s announcement opens the door to potential future collaborations
based on the outcome of the exploration into new endpoints.
About the Parkinson’s Institute and Clinical
The Parkinson’s Institute and Clinical Center is at the forefront of
patient care and therapy development. We are the nation’s only Institute
that provides patient care, basic science research, and clinical
research in one integrated model. Our unique freestanding organization
directly connects research to patient care – from the « bench to
bedside. » For 30 years, our team of epidemiologists, physicians,
scientists, and therapists, have been at the forefront of every clinical
and scientific discovery in the field of Parkinson’s research.
Since our inception, patients have come from 38 states and many foreign
countries for their care. We have managed more than 135 clinical
research trials, medically evaluating more than 95 different drugs and
therapies for Parkinson’s. The result: our Institute has been directly
involved in bringing every Parkinson’s drug currently available to the
market. The Institute is at the forefront of discovering and developing
the latest, most innovative treatments and therapies for people living
For more information visit www.thepi.org
or call (408) 734-2800.
Parkinson’s Institute and Clinical Center
Chris Di Salvo,
Source: Parkinson’s Institute and Clinical Center